Printer Friendly

U.S. patent covers neuralstem's small molecule compound.

GERMANTOWN, Md., February 22, 2017 -- Neuralstem, Inc. (CUR), a biopharmaceutical company focused on central nervous system therapies, announced a USPTO patent (No. 9,572,807) for NSI-189, the lead compound in the company's neurogenic small molecule program in development for the treatment of major depressive disorder.

[ILLUSTRATION OMITTED]

The patent has claims to protocols for using NSI-189 and related compounds for treatment of major depressive disorder.

Counterparts have been filed in Australia, Canada, Europe, Japan, Singapore and South Korea. These patents will expire in June 2035.

The new patent adds to the portfolio of over 20 U.S. and 120 foreign issued and pending patents that are owned or licensed to Neuralstem in the field of regenerative medicine.

Contact: http://www.neuralstem.com

COPYRIGHT 2017 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Patents
Publication:Stem Cell Business News
Date:Mar 6, 2017
Words:123
Previous Article:Grant supports company's R&D of therapies for type 1 diabetes.
Next Article:AHA honors study of stem cell stroke treatment.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters